Introduction {#s1}
============

Atrial fibrillation (AF) as the primary symptom occurs in 3.3% to 10.0% of emergency department (ED) admissions.[@R1] As to the ongoing ED crowding worldwide, an effective management for patients with symptomatic AF is mandatory.[@R2] Ideally, optimisation of patient management and resource allocation should be based on a time and cost- effective risk stratification.[@R4] Up to now, the prognosis prediction is merely derived from established cardiovascular risk scores and thromboembolic risk prediction tools as the CHA~2~DS~2~-VASc score; a biomarker based approach might be then helpful for identification of patients at increased risk for mortality during mid-term follow-up.[@R3]

Brain natriuretic peptide (BNP) and N-terminal pro-brain natriuretic peptide (NT-proBNP) are established prognostic markers for outcome and mortality in various fields of cardiovascular (CV) disease.[@R5] Cardiac troponins are sensitive biomarkers for cardiac damage and already slight elevations are associated with adverse outcome in CV disease.[@R9]

It was recently proposed that the combination of a biomarker-- approach might improve existing risk stratification tools in patients with AF.[@R8] The aim of the present study was then to evaluate the predictive value of both NT-proBNP and high-sensitive troponin T (hs-TnT) to predict mid-term mortality in symptomatic AF patients presenting to an ED.

Methods {#s2}
=======

Design/Setting {#s2a}
--------------

In this single-centre cohort study, consecutive adult patients presenting with AF at the ED of the Medical University of Vienna from 2012 to 2016 were eligible for inclusion.

Data acquisition {#s2b}
----------------

Following written consent, demographic data, current prescriptions, relevant comorbidities and type of AF according to the current guidelines, duration and AF symptoms were recorded. As guideline definitions for paroxysmal and persistent AF evolved during the study period, both classes have been merged for analysis.

Laboratory values and measurements {#s2c}
----------------------------------

Serum NT-proBNP and hs-TnT assays were processed on Cobas E602-Module (ECLIA, Roche Diagnostics GmbH, Mannheim, Germany) console with a coefficient of variation and the reference range of 5.7% and 0--14 ng/L for hs-TnT and 3.7% and 0--125 pg/mL for NT-proBNP. The limit of blank was 3 ng/L for hs-TnT, the limits of detection 5 ng/L for hs-TnT and 5 pg/mL for NT-proBNP (according to the CLSI EP17-A guideline).

Mortality data {#s2d}
--------------

Official 'all- cause death' data were provided by the Austrian death registry maintained by the national central statistical office (Statistik Austria, Guglgasse 13, A-1110 Vienna).

Statistics {#s2e}
----------

We present continuous data as median and 25% to 75% IQR, categorised data as absolute count and relative frequency (percentage, %). The entry time for the calculation of the observation period in patient-years (pry) was the first admission with AF at the study centre. Observation time was censored at the date of death or end of the follow-up. For the calculation of the prognostic value of NT-proBNP and hs-TnT, AF episodes with incomplete (only one or no biomarker value at the time of admission) cardiac biomarker information were excluded. To achieve appropriately sized groups including a centrally positioned one, we categorised NT-proBNP (Q~bnp~) and hs-TnT (Q~tnt~) into quintiles. To compare baseline data between NT-proBNP and hs-TnT quintiles, we used a χ^2^ test for categorised variables. We used the Kruskal-Wallis test for continuous data to test the null hypothesis of no difference because the normality assumption was not met for all baseline data. The unit of analysis of our cohort were admissions (episodes) for AF and included 20% patients, who presented with more than one AF episode. We performed our analysis at the level of episodes, allowing for correlation within patients with multiple episodes using variance component estimates for clustered observations. We calculated mortality rates per 100 pry for NT-proBNP and hs-TnT quintiles and their combinations. We used Cox proportional hazards regression to estimate the hazards of death with NT-proBNP and hs-TnT quintiles simultaneously as the main covariates. We extended the models to assess the independent association of NT-proBNP and hs-TnT with other covariates ([table 1](#T1){ref-type="table"}).

###### 

Association of cardiac biomarkers and mortality

                                     NT-proBNP   P values       hs-TnT    P values                  
  ---------------------------------- ----------- -------------- --------- ---------- -------------- ---------
  Model                                                                                             
   Unadjusted                        1.97†       1.71 to 2.26   \<0.001   1.99†      1.70 to 2.33   \<0.001
   Adjusted for clinical factors\*   1.53†       1.27 to 1.83   \<0.001   1.31†      1.10 to 1.55   0.002
   Adjusted for CHA~2~DS~2~-VASc     1.70†       1.43 to 2.03   \<0.001   1.52†      1.28 to 1.81   \<0.001
  Sensitivity analysis                                                                              
   First episode only                1.68†       1.39 to 2.04   \<0.001   1.91†      1.54 to 2.36   \<0.001
   Random effects models             2.34†       1.82 to 3.01   \<0.001   2.98†      2.19 to 4.03   \<0.001
   Continuous scale‡                 1.66        1.38 to 2.00   \<0.001   1.26       1.07 to 1.49   0.006

\*age, female gender, heart failure, chronic obstructive pulmonary disease, serum creatinine, arterial hypertension, coronary artery disease, hyperlipidaemia, diabetes mellitus, peripheral artery disease, history of stroke, history of transient ischemic attack, current smoking, pulmonary vein isolation, beta-blocker and diuretic therapy.

†HR for increase of biomarker quintile.

‡After natural log transformation.

We also calculated an alternative model with CHA~2~DS~2~-VASc as the summary integrative covariate of clinically relevant factors but did not model this covariable with the other factors to avoid multicollinearity. We used the Akaike information criterion for model comparison. We assessed first-order interactions of biomarkers by including interaction terms into the models and tested for deviation from linearity. We performed sensitivity analyses to assess the robustness of our multiepisode approach using the first episode only (ignoring other episodes of the same patients) or using random effects models. To assess the robustness of biomarker categorisation, we modelled biomarkers as covariables on a continuous scale after natural log transformation. We assumed that missing data were missing at random. Given the sample size, we decided not to use any methods of data imputation or replacement.

For data management and analysis, we used MS Excel and Stata 14 for Mac. Generally, a two-sided p value \<0.05 was considered statistically significant.

Results {#s3}
=======

Baseline characteristics {#s3a}
------------------------

### Patients and episodes {#s3a1}

In total 2574 episodes of 1754 patients (age 68 (IQR 58--75) years, female gender 1199 (44%), CHA~2~DS~2~-VASc 3 (IQR 1--4)) with symptomatic AF were available for analysis ([figure 1](#F1){ref-type="fig"}). Following exclusion of AF episodes with incomplete biomarker datasets, final analysis comprised 1780 episodes with both NT-proBNP and hs-TnT levels.

![Flow chart of patient inclusion. AF, atrial fibrillation.](heartjnl-2018-313145f01){#F1}

Median heart rate was at 122 (IQR 103--140) bpm. Paroxysmal/persistent AF was the most frequent type of AF in all biomarker subgroups. With increasing levels of NT-proBNP and hs-TnT, the hazard for permanent AF increased. The median duration of current AF episodes was 2 (IQR 1--4) and 3 (IQR 2--10) in the lowest, 20 (IQR 8--48) and 8 (IQR 3--48) hours in the highest respective NT-proBNP and hs-TnT quintiles. Duration of current AF correlated directly with biomarker levels. Cardiovascular risk factors were more prevalent in patients with higher biomarker levels ([tables 2 and 3](#T2 T3){ref-type="table"}).

###### 

Baseline characteristics by NT-proBNP

                             NT-proBNP         n       NT-proBNP          n     NT-proBNP          n       NT-proBNP           n     NT-proBNP           n       P values
  -------------------------- ----------------- ------- ------------------ ----- ------------------ ------- ------------------- ----- ------------------- ------- ----------
  Clinical characteristics                                                                                                                                       
   Age, years (IQR)          56 (48--66)       329     65 (57--73)        353   69 (61--75)        364     71 (66--77)         365   73 (67--81)         368     \<0.001
   Female gender, n (%)      74 (22)           329     136 (39)           353   152 (42)           365     188 (52)            365   178 (48)            368     \<0.001
   CHA~2~DS~2~-VASc (IQR)    1 (0--2)          275     2 (1--4)           330   3 (2--4)           346     3 (2--4)            357   3 (2--4)            360     \<0.001
  Laboratory                                                                                                                                                     
   hs-TnT, ng/L (IQR)        8.0 (5.0--14.0)   *329*   10.0 (6.0--17.0)   353   13.0 (8.0--25.0)   *365*   16.0 (10.0--29.0)   365   30.0 (19.0--57.0)   *368*   \<0.001
   Creatinine, mg/dL (IQR)   0.9 (0.8--1.1)    *326*   1.0 (0.8--1.1)     353   1.0 (0.9--1.2)     *363*   1.0 (0.8--1.2)      364   1.2 (1.0--1.6)      *366*   \<0.001
  Comorbidities                                                                                                                                                  
   Heart failure, n (%)      60 (18.2)         329     61 (17.3)          353   83 (22.7)          365     80 (21.9)           365   116 (31.5)          368     \<0.001
   Hypertension, n (%)       155 (47.1)        329     233 (66.0)         353   258 (70.7)         365     254 (69.6)          365   251 (68.2)          368     \<0.001
   DM, n (%)                 30 (9.1)          329     61 (17.3)          353   64 (17.5)          365     52 (14.3)           365   75 (20.4)           368     0.001
   TIA, n (%)                6 (2.0)           329     3 (0.9)            353   10 (2.7)           365     7 (1.9)             365   9 (2.5)             368     0.421
   Stroke, n (%)             7 (2.1)           329     12 (3.4)           353   21 (5.8)           365     25 (6.9)            365   27 (7.3)            368     0.006
   CAD, n (%)                20 (6.1)          329     44 (12.5)          353   65 (17.8)          365     82 (22.5)           365   115 (31.3)          368     \<0.001
   Previous MCI, n (%)       10 (3.0)          329     24 (6.8)           353   30 (8.2)           365     44 (12.1)           365   55 (15.0)           368     \<0.001
   PAD, n (%)                8 (2.4)           329     9 (2.6)            353   15 (4.1)           365     25 (6.9)            365   25 (6.8)            368     0.004
   Hyperlipidaemia, n (%)    96 (29.2)         329     104 (29.5)         353   136 (37.3)         365     126 (34.5)          365   103 (28.0)          368     0.031
   Current smoker, n (%)     20 (6.1)          329     16 (4.5)           353   16 (4.5)           365     21 (5.8)            365   20 (5.4)            368     0.17
   COPD, n (%)               15 (4.6)          329     24 (6.8)           353   27 (7.4)           365     33 (9.0)            365   57 (15.5)           368     \<0.001
  Medication                                                                                                                                                     
   Beta-blockers, n (%)      90 (27.4)         329     146 (41.4)         353   159 (43.6)         365     182 (49.9)          365   206 (56.0)          368     \<0.001
   Amiodaron, n (%)          41 (12.5)         329     73 (20.7)          353   69 (18.9)          365     77 (21.1)           365   79 (21.5)           368     0.016
   VKA, n (%)                57 (17.3)         329     102 (28.9)         353   133 (36.4)         365     113 (31.0)          365   112 (30.4)          368     \<0.001
   NOAC, n (%)               37 (11.3)         329     47 (13.3)          353   54 (14.8)          365     58 (15.9)           365   42 (11.4)           368     0.273
   Diuretics, n (%)          26 (7.9)          329     54 (15.3)          353   89 (24.4)          365     84 (23.0)           365   136 (37.0)          368     \<0.001

Baseline characteristics by all five quintiles of  NT-proBNP.

CAD, coronary artery disease, COPD, chronic obstructive pulmonary disease, DM, diabetes mellitus, hs-TnT, high-sensitive troponin T, MCI, myocardial infarction, NOAC, new oral anticoagulant, NT-proBNP, N-terminal pro-brain natriuretic peptide, PAD, peripheral artery disease, VKA, vitamin K antagonist.

###### 

Baseline characteristics by hs-TnT

                             hs-TnT           n     hs-TnT            n     hs-TnT            n     hs-TnT             n     hs-TnT              n     P values
  -------------------------- ---------------- ----- ----------------- ----- ----------------- ----- ------------------ ----- ------------------- ----- ----------
  Clinical characteristics                                                                                                                             
   Age, years (IQR)          58 (48--67)      210   62 (55--68)       284   69 (59--74)       456   72 (65--78)        405   73 (65--81)         424   \<0.001
   Female gender, n (%)      80 (38)          210   123 (43)          284   212 (46)          457   165 (41)           405   148 (35)            424   0.01
   CHA~2~DS~2~-VASc (IQR)    2 (1--3)         185   2 (1--3)          260   3 (2--4)          434   3 (2--4)           389   3 (2--4)            400   \<0.001
  Laboratory                                                                                                                                           
   hs-TnT, ng/L (IQR)        322 (112--720)   210   508 (182--1135)   284   789 (296--2044)   457   1441 (568--3249)   405   2946 (1195--6899)   424   \<0.001
   Creatinine, mg/dL (IQR)   0.9 (0.8--1.0)   208   0.9 (0.8--1.1)    283   1.0 (0.8--1.1)    453   1.1 (0.9--1.3)     404   1.2 (1.0--1.6)      424   \<0.001
  Comorbidities                                                                                                                                        
   Heart failure, n (%)      36 (17.1)        210   55 (19.4)         284   90 (19.7)         457   90 (22.2)          405   129 (30.4)          424   \<0.001
   Hypertension, n (%)       105 (50.0)       210   180 (63.4)        284   309 (67.6)        457   281 (69.4)         405   276 (65.1)          424   \<0.001
   DM, n (%)                 13 (6.2)         210   34 (12.0)         284   71 (15.5)         457   69 (17.0)          405   95 (22.4)           424   \<0.001
   TIA, n (%)                0 (0)            210   5 (1.8)           284   8 (1.8)           457   12 (3.0)           405   10 (2.4)            424   0.146
   Stroke, n (%)             2 (1.0)          210   13 (4.6)          284   22 (4.8)          457   23 (5.7)           405   32 (7.6)            424   0.011
   CAD, n (%)                9 (4.3)          210   24 (8.5)          284   60 (13.1)         457   101 (24.9)         405   132 ((31.1)         424   \<0.001
   Previous MCI, n (%)       5 (2.4)          210   13 (4.6)          284   32 (7.0)          457   47 (11.6)          405   66 (15.6)           424   \<0.001
   PAD, n (%)                1 (0.5)          210   6 (2.1)           284   17 (3.7)          457   25 (6.2)           405   33 (7.8)            424   \<0.001
   Hyperlipidaemia, n (%)    72 (34.3)        210   103 (36.3)        284   149 (32.6)        457   121 (29.9)         405   120 (28.3)          424   0.169
   Current smoker, n (%)     11 (5.2)         210   13 (4.6)          284   21 (4.6)          457   23 (5.7)           405   25 (5.9)            424   0.198
   COPD, n (%)               12 (5.7)         210   11 (3.9)          284   24 (5.3)          457   43 (10.6)          405   66 (15.6)           424   \<0.001
  Medication                                                                                                                                           
   Beta-blockers, n (%)      85 (40.5)        210   115 (40.5)        284   210 (46.0)        457   184 (45.4)         405   189 (44.6)          424   0.466
   Amiodaron, n (%)          32 (15.2)        210   46 (16.2)         284   88 (19.3)         457   88 (21.7)          405   85 (20.1)           424   0.227
   VKA, n (%)                58 (27.6)        210   84 (29.6)         284   155 (33.9)        457   114 (28.2)         405   106 (25.0)          424   0.06
   NOAC, n (%)               32 (15.2)        210   39 (13.7)         284   69 (15.1)         457   51 (12.6)          405   47 (11.1)           424   0.411
   Diuretics, n (%)          14 (6.7)         210   41 (14.4)         284   97 (21.2)         457   107 (26.4)         405   130 (30.7)          424   \<0.001

‡After natural log transformation. Baseline characteristics by all five quintiles of hs-TnT.

CAD, coronary artery disease, COPD, chronic obstructive pulmonary disease, DM, diabetes mellitus, hs-TnT, high-sensitive troponin T, MCI, myocardial infarction, NOAC, new oral anticoagulant, NT-proBNP, N-terminal pro-brain natriuretic peptide, PAD, peripheral artery disease, VKA, vitamin K antagonist.

The total observed time was 3433 pry with a median follow-up duration of 23 (IQR 4--38) months. A total of 162 patients deceased during mid-term follow-up; mortality rate was 4.72 per 100 pry. Mortality rate increased linearly by biomarker levels (p\<0.001).

### NT-proBNP, hs-TnT and mortality {#s3a2}

We could observe a significant crude association of mortality with both increasing NT-proBNP quintiles and increasing hs-TnT quintiles. In multivariate analysis, adjusting for age, female gender, heart failure, COPD, serum creatinine, arterial hypertension, coronary artery disease, hyperlipidaemia, diabetes mellitus, peripheral artery disease, history of stroke, history of TIA, current smoking, pulmonary vein isolation, beta-blocker and diuretic therapy, hazard for death increased with every quintile of NT-proBNP by 1.53 and by 1.31 with every quintile of hs-TnT ([table 3](#T3){ref-type="table"}, [figure 2](#F2){ref-type="fig"}). Adjustment for CHA~2~DS~2~-VASc resulted in an HR of 1.70 for each increase of NT-pro-BNP quintile and 1.52 for each increase of hs-TnT quintile for mortality ([table 3](#T3){ref-type="table"}).

![Mortality in patients presenting in an emergency department because of AF by NT-proBNP and hs-TnT (prediction model: Cox proportional-hazards regression; NT-proBNP and hs-TnT adjusted for the clinical risk factors age, female gender, heart failure, chronic obstructive pulmonary disease, serum creatinine, hypertension, coronary artery disease, hyperlipidaemia, diabetes mellitus, peripheral artery disease, stroke, current smoking, pulmonary vein isolation, beta-blocker therapy, diuretic therapy). AF, atrial fibrillation; NT-proBNP, N-terminal pro-brain natriuretic peptide; hs-TnT, high-sensitive troponin T.](heartjnl-2018-313145f02){#F2}

There was no interaction between NT-pro-BNP and hs-TnT on their effect on outcome. Sensitivity analysis indicated robust estimates regarding handling of correlated data and biomarker categorisation ([table 3](#T3){ref-type="table"}).

Discussion {#s4}
==========

Presentation and symptoms vary widely for patients with AF admitted to an ED; the demand for an improved risk stratification seems reasonable to facilitate optimal and cost-effective care.[@R14] The present study evaluated the value of cardiac biomarkers in predicting mortality in patients and we could clearly demonstrate that both elevated NT-proBNP and hs-Troponin T levels at the time of admission were strongly and independently associated with increased mid-term mortality.

NT-proBNP, hs-TnT and mortality in AF {#s4a}
-------------------------------------

NT-proBNP and cardiac troponins have been successfully evaluated to predict prognosis in various fields of cardiovascular medicine.[@R8] To our best knowledge, this is the first study investigating the predictive value of both NT-proBNP and hs-TnT for all-cause mortality in patients presenting because of symptomatic AF to an ED. We found that both elevated NT-proBNP and high hs-TnT levels at the time of admission are independently associated with increased mortality in patients presenting because of AF in an ED. Following adjustment for clinical factors, the hazard for death increases with every quintile of NT-proBNP by 1.53 and by 1.31 with every quintile of hs-TnT.

Comparing our findings to previous reports, some specifics have to be considered: the RELY study comprised symptomatic and asymptomatic patients with rather long-lasting AF with a well-controlled median heart rate of 72 (IQR 62--82) per minute[@R8] In contrast, in our present cohort, all patients were symptomatic, median heart rate exceeded 100 beats per minute and duration of AF episodes was short in general; these characteristics are typical for patients with symptomatic AF presenting to an ED, thus fostering the robustness of our findings for application as a risk stratification tool.[@R16] Second, Stoyanov *et al* have reported recently hs-TnT levels of patients with AF in a similar setting; in line with our observation, a direct association between symptomatic AF, biomarker levels and mortality has been observed. As this particular study did not focus primarily on symptomatic AF as the primary diagnosis as patients with other reasons for hs-TnT level elevations have been included, residual confounding cannot be excluded, however.[@R17] In contrast, our study comprised unselected patients seeking help because of symptoms primary due to AF reducing this potential risk of confounding significantly. Last, we could demonstrate a clear biological gradient as the hazard for death increases independently with every quintile of hs-TnT and NT-proBNP.

Pathophysiological considerations {#s4b}
---------------------------------

Cardiac troponins have been primarily introduced as sensitive biomarkers for the inclusion and exclusion of acute myocardial infarction; however, it has been previously shown that elevation of cardiac troponins might also indicate the severity of other non-cardiac-related conditions; as symptomatic AF is an abnormal physiological state, elevated levels of troponins might reflect an oxygen demand/delivery mismatch and changes in microvascular blood flow thus indicating the urgency or emergency of disease.[@R18] This hypothesis might further be strengthened by the fact that BNPs are mainly released in response to high wall tension during states of haemodynamic stress.[@R22]

Clinical implications {#s4c}
---------------------

EDs play a key role in the management of the inhomogeneous group of patients with AF[@R3]; the use of risk stratification tools is mandatory for a time-effective and cost-effective treatment and easily accessible biomarkers might assist in this goal-oriented and risk-oriented approach.[@R8] As to our observations, NT-proBNP and hs-TnT may serve as those ideal biomarkers for identification of patients with symptomatic AF at risk; due to the increased risk of all-cause mortality, an extensive screening and more aggressive treatment stratified should be considered in all patients with AF with elevated NT-proBNP or/and hs-TnT levels presenting to an ED.

Strengths and limitations {#s4d}
-------------------------

The present study inherits all known limitations of a prospective observational study design that have to be acknowledged; those limitations are not limited to individual patient profiles, management at the ED and in further care only. However, this study covers a large cohort of consecutive patients within a limited and short time frame that decreases the potential negative impact on our conclusions. Due to the nature of an ED setting, only 1780 of a total 2574 episodes were available for analysis as to missing biomarker data; however, baseline characteristics between those included and excluded showed no significant differences lowering the potential impact of this limitation ([table 4](#T4){ref-type="table"}). Besides the clear demonstration of a biological gradient between biomarker levels and mid-term mortality, the probably greatest strength of our study is all-cause mortality being the primary outcome measure; as the issuance of death certificates is mandatory in Austria and registered by a central, state-controlled office, information bias can be nearly excluded. Due to our single-centre design, however, our results will not be fully generalisable to other settings and populations; our results ideally need confirmation in larger populations and this might allow then to estimate conceivable cut-off values for risk estimation and stratification that we were not able to due to sample size limitations.

###### 

Baseline characteristics by biomarker availability

                            All episodes   Incomplete information   Both biomarkers available
  ------------------------- -------------- ------------------------ ---------------------------
  Clinical presentation                                             
   Age, years (IQR)         68 (58--75)    67 (56--75)              68 (59--75)
   Female gender, n (%)     1199 (44)      472 (48)                 728 (41)
   CHA~2~DS~2~-VASc (IQR)   3 (1--4)       2 (1--4)                 3 (2--4)
  Comorbidities                                                     
   Heart failure, n (%)     628 (22.8)     228 (23.4)               400 (22.5)
   Hypertension, n (%)      1696 (61.6)    548 (56.3)               1151 (64.7)
   DM, n (%)                401 (14.6)     120 (12.3)               282 (15.8)
   TIA, n (%)               46 (1.7)       11 (1.1)                 35 (2.0)
   Stroke, n (%)            141 (5.1)      49 (5.0)                 92 (5.2)
   CAD, n (%)               458 (16.6)     132 (13.6)               326 (18.3)
   Previous MCI, n (%)      219 (8.0)      56 (5.7)                 163 (9.2)
   PAD, n (%)               107 (3.9)      25 (2.6)                 82 (4.6)
   Hyperlipidaemia(%)       840 (30.5)     277 (28.4)               565 (31.7)
   Current smoker, n (%)    130 (4.7)      37 (3.8)                 93 (5.2)
   COPD, n (%)              256 (9.3)      100 (10.3)               156 (8.8)
  Medication                                                        
   Beta-blockers, n (%)     1133 (41.1)    382 (39.2)               751 (42.2)
   Amiodaron)               477 (17.3)     138 (14.2)               339 (19.0)
   VKA, n (%)               766 (27.8)     249 (25.6)               517 (29.0)
   NOAC, n (%)              355 (12.9)     120 (12.3)               237 (13.3)
   Diuretics, n (%)         567 (20.6)     180 (18.5)               389 (21.9)

CAD, coronary artery disease; COPD, chronic obstructive pulmonary disease; DM, diabetes mellitus; hs-TnT-sensitive troponin t, MCI, myocardial infarction;NOAC, new oral anticoagulant; NT-proBNP, N-terminal pro-brain natriuretic peptide; PAD, peripheral artery disease; VKA, vitamin K antagonist.

Conclusion {#s5}
==========

Indicating substantially increased mid-term mortality in patients with symptomatic AF, NT-proBNP and hs-TnT could help deciding whether hospitalisation and/or specific long-term management are expedient in high-risk patients. Due to the increased risk of all-cause mortality, an extensive screening and more aggressive treatment stratified by elevated NT-proBNP or/and hs-TnT might be considered in AF-patients presenting to an ED.

###### Key messages

What was already known on this subject?
---------------------------------------

-   It is common knowledge that atrial fibrillation (AF) is regarded as a risk factor for increased mortality but information on specific patient subgroups at risk is scarce. N-terminal pro-brain natriunatriureticde (NT-proBNP) and cardiactroponins are known, powerful predictors of prognosis in various fields of cardiovascular medicine. It was recently proposed that cardiac troponins and NT-proBNP improve existing risk stratification in patients with AF.

What might this study add?
--------------------------

-   Patients with symptomatic AF are at a substantial risk for increased mortality (4.72/100 pry) during follow-up. Elevated NT-proBNP and high-sensitive troponin T (hs-TnT) levels are capable to predict mid-term outcome independently: following adjustment for established risk factors, hazards for death increases with every quintile of NT-proBNP by 1.53 - (HR; 95% CI 1.27 to 1.83; p\<0.001) and by 1.31 (HR; 95% CI 1.10 to 1.55; p=0.002) with every quintile of hs-TnT).

How might this impact on clinical practice?
-------------------------------------------

-   Indicating substantially increased mid-term mortality in patients with symptomatic AF,  NT-proBNP and hs-TnT  could help to decide whether hospitalisation and/or specific long-term management are expedient in high-risk patients. Due to the increased risk of all-cause mortality, an extensive screening and more aggressive treatment stratified by elevated NT-proBNP and hs-TnT might be considered in patients with AF presenting to an emergency department.
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